Latest News

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

In case you missed it, this week we had news about the first commercial treatment of Zevaskyn for RDEB, the global prevalence of HS, a new STAT6 degrader for AD, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

John Barbieri, MD, MBA, discusses how deteriorating prior authorization processes are compromising access to essential dermatologic therapies.

An updated review offers effective alternatives to hydroquinone for melasma treatment, including thiamidol and natural agents, with improved safety profiles.

A meta-analysis of over 800,000 patients shows JAK inhibitors are generally as safe as TNF antagonists for various purposes.

Galderma initiates a pivotal study on nemolizumab, targeting Chronic Pruritus of Unknown Origin, aiming to provide relief for this challenging condition.

Explore the emerging concept of PDE4 inhibitor-responsive dermatoses, offering innovative nonsteroidal treatments for chronic inflammatory skin conditions.

President Biden's Mohs surgery highlights the need for equitable access to this effective skin cancer treatment, emphasizing its benefits and ongoing disparities.

Explore the long-term efficacy and safety of ligelizumab for CSU, highlighting self-administration success and significant symptom control.

FDA proposes adding bemotrizinol to sunscreen ingredients, enhancing UV regulations and protection options for consumers for the first time since 1999.

A new global study reveals hidradenitis suppurativa affects 1 in every 100 people, highlighting the need for increased awareness and improved health care strategies.